We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
+$128M
Cap. Flow
+$26.2M
Cap. Flow %
2.17%
Top 10 Hldgs %
56.76%
Holding
362
New
28
Increased
88
Reduced
207
Closed
28

Top Buys

Rank Stock Value
1
TME icon
Tencent Music
TME
+$28.3M
2
LEGN icon
Legend Biotech
LEGN
+$20.2M
3
TCOM icon
Trip.com Group
TCOM
+$16M
4
STAA icon
STAAR Surgical
STAA
+$10.7M
5
ZLAB icon
Zai Lab
ZLAB
+$7.74M

Top Sells

Rank Stock Value
1
BEKE icon
KE Holdings
BEKE
+$21.9M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$10.8M
3
NIO icon
NIO
NIO
+$10.3M
4
LI icon
Li Auto
LI
+$8.53M
5
BZ icon
Kanzhun
BZ
+$8.18M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 36.91%
2 Technology 25.51%
3 Communication Services 14.94%
4 Healthcare 9.44%
5 Real Estate 3.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BA icon
301
Boeing
BA
$168B
$205K 0.02%
+1,074
New +$176K
DDOG icon
302
Datadog
DDOG
$89.3B
$204K 0.02%
2,775
-91
-3% -$7.11K
ENTA icon
303
Enanta Pharmaceuticals
ENTA
$376M
$203K 0.02%
4,369
-12
-0.3% -$547
PLD icon
304
Prologis
PLD
$137B
$200K 0.02%
+1,776
New +$197K
SRNE
305
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$198K 0.02%
223,808
+22,818
+11% +$30.3K
COGT icon
306
Cogent Biosciences
COGT
$6.91B
$196K 0.02%
16,975
+2,585
+18% +$32K
CHRS icon
307
Coherus Oncology
CHRS
$225M
$195K 0.02%
24,587
+6,114
+33% +$47K
ICPT
308
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$172K 0.01%
13,932
-1,576
-10% -$22.3K
PTGX icon
309
Protagonist Therapeutics
PTGX
$8.87B
$169K 0.01%
15,482
-8,366
-35% -$70.6K
OCGN icon
310
Ocugen
OCGN
$427M
$168K 0.01%
129,498
-3,440
-3% -$5.36K
ADMA icon
311
ADMA Biologics
ADMA
$1.96B
$161K 0.01%
41,376
+1,518
+4% +$4.68K
GERN icon
312
Geron
GERN
$949M
$161K 0.01%
66,662
+28,724
+76% +$64.3K
EQRX
313
DELISTED
EQRx, Inc. Common Stock
EQRX
$158K 0.01%
64,425
+24,197
+60% +$95.3K
MYGN icon
314
Myriad Genetics
MYGN
$528M
$157K 0.01%
10,822
-961
-8% -$17.9K
ALLK
315
DELISTED
Allakos
ALLK
$141K 0.01%
+16,749
New +$116K
VTRS icon
316
Viatris
VTRS
$20.3B
$137K 0.01%
12,294
-3,263
-21% -$34.1K
NCLH icon
317
Norwegian Cruise Line
NCLH
$9.13B
$130K 0.01%
10,598
– –
KZR
318
DELISTED
Kezar Life Sciences
KZR
$129K 0.01%
1,827
+145
+9% +$10.8K
DSGN icon
319
Design Therapeutics
DSGN
$749M
$128K 0.01%
+12,523
New +$170K
MRSN
320
DELISTED
Mersana Therapeutics
MRSN
$128K 0.01%
874
+286
+49% +$48.3K
IBRX icon
321
ImmunityBio
IBRX
$7.46B
$125K 0.01%
24,706
-3,098
-11% -$17K
KPTI icon
322
Karyopharm Therapeutics
KPTI
$174M
$124K 0.01%
2,434
-628
-21% -$43.5K
PMVP icon
323
PMV Pharmaceuticals
PMVP
$64M
$121K 0.01%
13,884
-6,000
-30% -$64K
SGMO
324
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$116K 0.01%
37,007
+9,284
+33% +$36K
PNT
325
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$113K 0.01%
15,530
+5,318
+52% +$39.5K
11 12
13
14 15

Similar funds

VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return
TAM
Troy Asset Management London, United Kingdom $3.35B AUM 11.7% 1-Year Est. Return
CS
CapitalatWork SA Auderghem $3.35B AUM
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
QCG
Quadrant Capital Group Cincinnati, Ohio $3.34B AUM 29.16% 1-Year Est. Return

E Fund Management's Q4 2022 Portfolio in Review

As of Q4 2022, E Fund Management held 362 positions worth $1.2B, up 12% from $1.07B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

E Fund Management's Q4 2022 filing shows 28 new, 88 increased, 207 reduced and 28 closed positions. Its largest new stake was Akero Therapeutics: 9,604 shares worth $526K. The largest sale was KE Holdings, an estimated $21.9M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 37% of assets, up from 34% a quarter earlier, followed by Technology and Communication Services.

  • E Fund Management's largest Q4 2022 buy was Akero Therapeutics: 9,604 shares worth $526K.
  • E Fund Management added most to Tencent Music in Q4 2022, an estimated $28.3M increase.
  • E Fund Management's biggest Q4 2022 reduction was KE Holdings, cutting an estimated $21.9M.
  • E Fund Management fully exited Li Auto in Q4 2022, selling an estimated $8.53M.
  • E Fund Management's ten largest holdings make up 57% of its $1.2B portfolio in Q4 2022.
  • E Fund Management opened 28 new positions and closed 28 in Q4 2022.
  • E Fund Management's portfolio value rose 12% quarter-over-quarter to $1.2B.

Based on E Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.